Business
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
BOSTON, August 12, 2025--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/c1363731d9acc21bfbb64c573fe5f6af"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lKnjwQNJBAbGlzumjxLeiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c1363731d9acc21bfbb64c573fe5f6af","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NfKef2oplyTxEplZqCFanw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c1363731d9acc21bfbb64c573fe5f6af","width":1200,"height":385}},"lazy":false},{"type":"text","content":"Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, August 12, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the launch of a new Founded Entity Celea Therapeutics ("Celea").","length":341,"tagName":"p"},{"type":"text","content":"Celea’s mission is to deliver therapies that transform the lives of people with serious respiratory diseases. Its lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disease. Sven Dethlefs, PhD, has been appointed to lead Celea, bringing deep expertise and a clear vision to accelerate the program's advancement. The launch of Celea reflects PureTech’s commitment to advancing differentiated programs through focused, capital-efficient structures with seasoned leadership.","length":708,"tagName":"p"},{"type":"text","content":"Dr. Dethlefs is a proven pharmaceutical executive with more than 25 years of experience in global commercialization, R&D strategy, business development, and operations. He has played a central role at PureTech, driving forward the deupirfenidone program for more than a year. Prior to joining PureTech, Dr. Dethlefs served as CEO...